Takeda Escapes COVID Impact With 2% Underlying Growth

R&D Spend To Rise 15%

Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market. 

Takeda Tokyo HQ entrance
Takeda spends to progress Wave 1 pipeline • Source: Takeda

While the pandemic reduced patient visits with an impact on some areas including neuroscience at Takeda Pharmaceutical Co. Ltd., this was offset by gains for certain other products and lower travel expenses, meaning the overall net business impact for the Japanese firm last fiscal year was “not material.”

In announcing its results for the 12 months ended 31 March, Japan’s largest pharma company said it had managed to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip